James Jumper, MD
Retina Specialist · San Francisco, CANPI 1609844687
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,375 of the $12,759 with a category attached, or 73.5%. Dutch Ophthalmic, USA accounts for 91.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $9,508 and has fallen 96.1% since, to $372 in 2025.
Across 32 payments — averaging $398.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dutch Ophthalmic, USA$12K
- Genentech USA, Inc.$578
- Alcon$187
- Regeneron Healthcare Solutions, Inc.$143
- Eyepoint US, Inc.$86
- Astellas Pharma US Inc$30
- plus $111 from 4 others
Across 31 payments — averaging $1994.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$51K
- AbbVie$11K
What the payments were for
- Consulting fees$2,25018%
- Speaking & faculty fees$9,37573%
- Food & beverage$1,1349%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dutch Ophthalmic, USA | 4 | $11,625 |
| Genentech USA, Inc. | 13 | $578 |
| Alcon | 3 | $187 |
| Regeneron Healthcare Solutions, Inc. | 3 | $143 |
| Eyepoint US, Inc. | 4 | $86 |
| Astellas Pharma US Inc | 1 | $30 |
| Carl Zeiss Meditec USA, Inc. | 1 | $30 |
| Harrow Eye, LLC | 1 | $29 |
| AbbVie | 1 | $28 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVA Ophthalmic Surgical System$9,375
- EVA, combined machine$2,250
- TISSUEBLUE$2,250
- Constellation$105
- EYLEA$103
How this compares
$12,759 in reported general payments places this provider in the 75th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 128 | $6,721 |
| Difluprednate | 38 | $3,595 |
| Brimonidine Tartrate | 24 | $826 |
| Timolol Maleate | 38 | $786 |
| Ketorolac Tromethamine | 20 | $639 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 77 | $471 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 45 | $424 |
| Latanoprost | 59 | $351 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $225 |
| ErythromycinErythromycin Base | 14 | $138 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in San Francisco
- Judy ChenSan Francisco$15K
- Andrew CalmanSan Francisco$13K
- Malini PasrichaSan Francisco$13K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.